Edesa Biotech Inc (EDSA)

$1.48 0.00 (N/A)
Market Cap 12.33M
Revenue (ttm) 0.00
Net Income (ttm) -7.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 34,600
Avg Vol 51,224
Day's Range N/A - N/A
Shares Out 8.33M
Stochastic %K 44%
Beta 0.13
Analysts Strong Sell
Price Target $12.00

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic aller...

Industry: Biotechnology
Sector: Healthcare
Phone: 289 800 9600
Address:
100 Spy Court, Markham, Canada
GeeJoon
GeeJoon Jan. 10 at 9:25 PM
$EDSA it is rare for a micro biotech getting gov fund/grant, not one but two incluing US and CAD, but have to be aware that even supported by BARDA like Athersys could not meet the end point and still bankrupted
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 9 at 5:25 PM
$EDSA
0 · Reply
GeeJoon
GeeJoon Jan. 9 at 5:09 PM
$EDSA EB01 seems like dead, no medical article about ACD
0 · Reply
GeeJoon
GeeJoon Jan. 9 at 3:02 PM
$EDSA Snitched another 10,000 free shares by Par
1 · Reply
KennyP007
KennyP007 Jan. 9 at 2:09 AM
$EDSA Replace the word Car with Stock and it discribes this company and stock 100%%% https://youtu.be/3Fw0OvKFKhw?si=sub-euBY3LLbwYwE
0 · Reply
GeeJoon
GeeJoon Jan. 8 at 5:21 PM
$EDSA what i have learnt from investing EDSA 1. it is impossible for micro biotech to commercialise a drug without the help of big pharma, listing the company only for capturing other people's money to fulfil the dream of those doctors/scientists 2. biotech always exaggerate drug efficacy and understimate the time and cost of trial 3. if a drug is good enough to threaten the benefit of industry, big pharma would acquire it asap like in P1/P2, if no one show interest after completing P2, the drug is not novel technology in big pharma's eyes
0 · Reply
Moneyybaggs
Moneyybaggs Jan. 8 at 12:19 PM
$EDSA HE’S BAAAAAAAACK!!! LOVE IT!!!
1 · Reply
Moneyybaggs
Moneyybaggs Jan. 8 at 10:39 AM
$EDSA Happy New Year Eddy!!! We miss your rants! I hope you get released from the penalty box soon. 2026 is TURDESA’s year to EXPLODE!!! FMTT!!! And………. FYPP!!!
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 7 at 3:11 PM
$EDSA Current Stock Price: $1.53
0 · Reply
Peaceouty
Peaceouty Jan. 6 at 8:11 PM
$EDSA of you like scam stocks check out CANF. 4-5ish market cap. Impressive fundamentals and pipeline.
1 · Reply
Latest News on EDSA
Edesa Biotech Reports Fiscal Year 2025 Results

Dec 12, 2025, 4:20 PM EST - 4 weeks ago

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech Announces Upcoming Conference Schedule

Oct 31, 2025, 4:30 PM EDT - 2 months ago

Edesa Biotech Announces Upcoming Conference Schedule

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Oct 28, 2025, 7:45 AM EDT - 2 months ago

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Aug 8, 2025, 4:35 PM EDT - 5 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 8 months ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Apr 28, 2025, 4:30 PM EDT - 9 months ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech Announces Chief Financial Officer Transition

Apr 4, 2025, 4:15 PM EDT - 10 months ago

Edesa Biotech Announces Chief Financial Officer Transition

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 14, 2025, 4:15 PM EST - 11 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Feb 13, 2025, 7:00 AM EST - 11 months ago

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Edesa Biotech Reports Fiscal Year 2024 Results

Dec 13, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2024 Results

Edesa Biotech's Founder Makes Strategic Investment in the Company

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Edesa Biotech's Founder Makes Strategic Investment in the Company

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Sep 13, 2024, 7:38 PM EDT - 1 year ago

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Aug 9, 2024, 4:20 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Jun 24, 2024, 8:20 AM EDT - 1 year ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Edesa Biotech to Participate in Upcoming Investor Conferences

Apr 2, 2024, 9:00 AM EDT - 1 year ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Mar 7, 2024, 8:45 AM EST - 2 years ago

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Mar 4, 2024, 4:30 PM EST - 2 years ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Feb 9, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Jan 4, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Edesa Biotech Reports Fiscal Year 2023 Results

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Nov 20, 2023, 4:05 PM EST - 2 years ago

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Oct 25, 2023, 9:10 AM EDT - 2 years ago

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Oct 12, 2023, 12:15 PM EDT - 2 years ago

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Oct 12, 2023, 12:10 PM EDT - 2 years ago

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Edesa Biotech Announces One-for-Seven Reverse Share Split

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Sep 28, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Aug 9, 2023, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Jul 26, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 27, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Jun 15, 2023, 8:00 AM EDT - 2 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023, 4:30 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Edesa Biotech to Participate in Swiss Biotech Day

Apr 20, 2023, 8:30 AM EDT - 2 years ago

Edesa Biotech to Participate in Swiss Biotech Day

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Apr 4, 2023, 8:45 AM EDT - 3 years ago

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Mar 23, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Mar 15, 2023, 8:10 AM EDT - 3 years ago

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 10, 2023, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Feb 1, 2023, 8:15 AM EST - 3 years ago

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Jan 17, 2023, 8:30 AM EST - 3 years ago

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Dec 20, 2022, 8:30 AM EST - 3 years ago

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Edesa Biotech Reports Fiscal Year 2022 Results

Dec 16, 2022, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal Year 2022 Results

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Dec 2, 2022, 8:00 AM EST - 3 years ago

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Nov 3, 2022, 9:00 AM EDT - 3 years ago

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Sep 30, 2022, 8:00 AM EDT - 3 years ago

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Sep 8, 2022, 4:30 PM EDT - 3 years ago

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Sep 7, 2022, 8:00 AM EDT - 3 years ago

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

GeeJoon
GeeJoon Jan. 10 at 9:25 PM
$EDSA it is rare for a micro biotech getting gov fund/grant, not one but two incluing US and CAD, but have to be aware that even supported by BARDA like Athersys could not meet the end point and still bankrupted
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 9 at 5:25 PM
$EDSA
0 · Reply
GeeJoon
GeeJoon Jan. 9 at 5:09 PM
$EDSA EB01 seems like dead, no medical article about ACD
0 · Reply
GeeJoon
GeeJoon Jan. 9 at 3:02 PM
$EDSA Snitched another 10,000 free shares by Par
1 · Reply
KennyP007
KennyP007 Jan. 9 at 2:09 AM
$EDSA Replace the word Car with Stock and it discribes this company and stock 100%%% https://youtu.be/3Fw0OvKFKhw?si=sub-euBY3LLbwYwE
0 · Reply
GeeJoon
GeeJoon Jan. 8 at 5:21 PM
$EDSA what i have learnt from investing EDSA 1. it is impossible for micro biotech to commercialise a drug without the help of big pharma, listing the company only for capturing other people's money to fulfil the dream of those doctors/scientists 2. biotech always exaggerate drug efficacy and understimate the time and cost of trial 3. if a drug is good enough to threaten the benefit of industry, big pharma would acquire it asap like in P1/P2, if no one show interest after completing P2, the drug is not novel technology in big pharma's eyes
0 · Reply
Moneyybaggs
Moneyybaggs Jan. 8 at 12:19 PM
$EDSA HE’S BAAAAAAAACK!!! LOVE IT!!!
1 · Reply
Moneyybaggs
Moneyybaggs Jan. 8 at 10:39 AM
$EDSA Happy New Year Eddy!!! We miss your rants! I hope you get released from the penalty box soon. 2026 is TURDESA’s year to EXPLODE!!! FMTT!!! And………. FYPP!!!
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 7 at 3:11 PM
$EDSA Current Stock Price: $1.53
0 · Reply
Peaceouty
Peaceouty Jan. 6 at 8:11 PM
$EDSA of you like scam stocks check out CANF. 4-5ish market cap. Impressive fundamentals and pipeline.
1 · Reply
Bullforelife
Bullforelife Jan. 6 at 5:35 PM
$EDSA Howdy all, Happy New Year, and all that Jazz. I see Ed has exited... Stocktwits, Edsa or both. Anyway, I see a HBC tribute band has started up. I last conversed with HBC back in March 2025. He had told me he had been unwell... actually very unwell. He asked me not say exactly... but, I've not had a response from HBC not far off 10 months. HBC was (and hopefully still is) the right side of crazy. A big 👋if you're keeping an eye on here. As for me, I'm still in a death dive with this lovable POS. But ultimately I'm
0 · Reply
Peaceouty
Peaceouty Jan. 6 at 4:48 PM
$EDSA Shouldn’t this be in phase 10b by now?
0 · Reply
GeeJoon
GeeJoon Jan. 6 at 12:45 AM
$EDSA from covid $8 to $1, then rs 7:1 from $7 to now almost $1 again, how crazy this stock demolished 99% of your investment, and even now no bp or inst would step in, EB01 is a joke, 1% cream doing good in P2, but management waste all money to do trial on 0.5% and 2.0% cream to prove EB01 is not more the better, then sp dropped 60%, how stupid par exceute all these decision
0 · Reply
GeeJoon
GeeJoon Jan. 5 at 10:07 PM
$EDSA they just simply removed EB07 from slides, lol what a clown show, complete fraud, promoting EB07 for a year to scam investors then remove silently
0 · Reply
GeeJoon
GeeJoon Jan. 5 at 9:57 PM
$EDSA don't invest, this pos will go sub 1 for sure in 2026
0 · Reply
EireTrader
EireTrader Jan. 4 at 11:23 PM
$EDSA .. Investor Pack updated Website Updated "Additional uses for Paridiprubart may be available for other diseases"
2 · Reply
Treb3k
Treb3k Jan. 4 at 2:33 AM
$EDSA they added two more sites. unfortunately, i think the reality on the lack of communication continues to be that they dont have anything positive to share.
0 · Reply
GeeJoon
GeeJoon Jan. 1 at 10:20 AM
$EDSA i guess they have submitted EB06 P2 trial application to FDA if they want it starts in mid 2026
0 · Reply
HotBigCoins
HotBigCoins Dec. 31 at 3:27 PM
$EDSA hi everyone! I'm the guy that thought we would take off and held 6 years and sold for a huge loss.
4 · Reply
AllPenniesNoDividends
AllPenniesNoDividends Dec. 30 at 5:50 PM
$EDSA Tax harvest selling gone? Was it a whale that was trying to get out that took it to $1.28??
0 · Reply
Treb3k
Treb3k Dec. 30 at 2:03 PM
$EDSA no december update to the CTDG page for paridiprubart
0 · Reply
HopehelpsU
HopehelpsU Dec. 30 at 2:00 PM
$EDSA Snitches get Stitches....
0 · Reply